Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07826195) titled 'A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors' on Sept. 13.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd.

Condition: Advanced Gastrointestinal Tumors

Intervention: Drug: Injectable ALK-N001

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2026

Target Sample Size: 174

To know more, visit https://clinicaltrials.gov/study/NCT07826195

Pub...